MimiVax LLC and Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. announce exclusive licensing agreement on SurVaxM for glioblastoma treatment in China

Buffalo-based clinical-stage biotechnology company MimiVax, a Roswell Park Comprehensive Cancer Center spinoff, set to work with leading healthcare group in China to provide promising immunotherapy BUFFALO, N.Y. and SHANGHAI, Nov. 18, 2019 /PRNewswire/ --…

Continue Reading MimiVax LLC and Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. announce exclusive licensing agreement on SurVaxM for glioblastoma treatment in China